加载中...

MedXY News - biomarkers

MedXY AI/MedXY News/Tag: biomarkers

MedXY News

EnglishTag

biomarkers

78 all articles · 20 / page

Ask MedXY AI

clinical trial immunotherapy type 2 diabetes heart failure obesity clinical trials atrial fibrillation Cardiology biomarkers oncology cardiovascular risk public health Hypertension critical care Alzheimer's disease artificial intelligence breast cancer nutrition diabetes cardiovascular disease Pediatrics chronic kidney disease

Latest news

Tag

$Genomic Therapy Matching in Rare and Refractory Cancers: Clinical Utility and Survival Outcomes from the MoST Program$

Genomic Therapy Matching in Rare and Refractory Cancers: Clinical Utility and Survival Outcomes from the MoST Program

This review synthesizes findings from the Australian MoST program, demonstrating that genomically matched therapies significantly improve overall survival in advanced solid tumors only when supported by high-level prospective clinical trial

Section: Clinical UpdatesMar 6, 2026

Prognostic Significance of Dephospho-Uncarboxylated Matrix Gla-Protein in Heart Failure: Insights into Vascular Calcification and Therapeutic Implications

Prognostic Significance of Dephospho-Uncarboxylated Matrix Gla-Protein in Heart Failure: Insights into Vascular Calcification and Therapeutic Implications

A large-scale cohort study identifies dpucMGP as a robust predictor of mortality and hospitalization in heart failure, revealing its role in mediating warfarin-associated risks and its association with systemic proteomic pathways including

Section: CardiologyMar 6, 2026

Plasma GFAP and NfL Levels Predict Acute Brain Injury and Poor Outcomes in Pediatric ECMO

Plasma GFAP and NfL Levels Predict Acute Brain Injury and Poor Outcomes in Pediatric ECMO

This multi-center study demonstrates that serial monitoring of plasma GFAP and NfL biomarkers can detect acute brain injury in pediatric ECMO patients before imaging diagnosis, significantly correlating with long-term survival and functiona

Section: Critical CareMar 3, 2026

Plasma GFAP and NfL as Real-Time Predictors of Brain Injury and Long-Term Disability in Pediatric ECMO

Plasma GFAP and NfL as Real-Time Predictors of Brain Injury and Long-Term Disability in Pediatric ECMO

A prospective study demonstrates that rising levels of plasma GFAP and NfL precede neuroimaging-confirmed brain injury in children on ECMO. These biomarkers are also strongly associated with mortality and long-term functional impairment, of

Section: Critical CareMar 3, 2026

Expanding the Proteomic Landscape of Venous Thromboembolism: Novel Biomarkers and Causal Insights from Large-Scale Cohort Meta-Analyses

Expanding the Proteomic Landscape of Venous Thromboembolism: Novel Biomarkers and Causal Insights from Large-Scale Cohort Meta-Analyses

A groundbreaking large-scale proteomic study identified 15 novel plasma markers for venous thromboembolism, highlighting biological pathways in extracellular matrix regulation and vascular senescence.

Section: CardiologyMar 2, 2026

Beyond MELD: The Liver Immune Frailty Index (LIFI) Predicts Post-Transplant Mortality with High Precision

Beyond MELD: The Liver Immune Frailty Index (LIFI) Predicts Post-Transplant Mortality with High Precision

Researchers have developed the Liver Immune Frailty Index (LIFI), a biomarker-based tool using fractalkine and MMP3 to predict post-liver transplant mortality. With a C-statistic of 0.83, LIFI identifies high-risk candidates, potentially tr

Section: GastroenterologyFeb 22, 2026

Pregnancy as a Window to Longevity: Maternal Biomarkers at 29 Weeks Predict Long-Term Cardiovascular Risk

Pregnancy as a Window to Longevity: Maternal Biomarkers at 29 Weeks Predict Long-Term Cardiovascular Risk

A Danish cohort study demonstrates that specific pregnancy biomarkers, particularly sFlt-1 and hs-cTnI measured at 29 weeks, significantly enhance the prediction of long-term cardiovascular disease risk in women, independent of traditional

Section: CardiologyFeb 23, 2026

Neurofilament Light Chain: A High-Performance Biomarker for Differentiating bvFTD from Primary Psychiatric Disorders

Neurofilament Light Chain: A High-Performance Biomarker for Differentiating bvFTD from Primary Psychiatric Disorders

This systematic review confirms that Neurofilament Light Chain (NfL) in blood and CSF effectively distinguishes behavioral variant frontotemporal dementia from psychiatric disorders, offering a powerful tool for early and accurate diagnosis

Section: NeurologyFeb 14, 2026

LOAD Polygenic Risk in Early-Onset Alzheimer’s: Insights into Synaptic Dysfunction and Amyloid Pathophysiology

LOAD Polygenic Risk in Early-Onset Alzheimer’s: Insights into Synaptic Dysfunction and Amyloid Pathophysiology

A comprehensive study explores how polygenic risk scores for late-onset Alzheimer’s disease (LOAD) influence early-onset (EOAD) cases. While these scores do not independently predict EOAD onset or cognitive decline, they reveal significant

Section: NeurologyFeb 14, 2026

Biologically Informed p-tau217 Cutoffs: Refining Alzheimer’s Diagnosis Across Diverse Patient Profiles

Biologically Informed p-tau217 Cutoffs: Refining Alzheimer’s Diagnosis Across Diverse Patient Profiles

Standard single cutoffs for plasma p-tau217 are significantly confounded by kidney function, BMI, and anemia. A new study demonstrates that subgroup-specific or double-cutoff strategies markedly improve diagnostic accuracy and cost-effectiv

Section: NeurologyFeb 7, 2026

Beyond Concentration: The MUCQ Score Redefines Chronic Bronchitis Identification

Beyond Concentration: The MUCQ Score Redefines Chronic Bronchitis Identification

Researchers introduce the Mucin Quantitative Score (MUCQ), a novel metric combining mucin concentration and composition. Validated in the SPIROMICS cohort, MUCQ outperforms traditional total mucin measurements in identifying chronic bronchi

Section: newsFeb 3, 2026

Proteomic Signatures in Atrial Fibrillation: Deciphering the Risk of Heart Failure Hospitalization and Ejection Fraction Phenotypes

Proteomic Signatures in Atrial Fibrillation: Deciphering the Risk of Heart Failure Hospitalization and Ejection Fraction Phenotypes

This study identifies key plasma biomarkers—including NT-proBNP, FGF-23, and GDF-15—that predict heart failure hospitalization in patients with atrial fibrillation. Findings also reveal distinct pathophysiological pathways for HFrEF and HFp

Section: CardiologyJan 22, 2026

CYTOscore: A Triple-Cytokine Signature Predicts Survival and Response to Chemoradiotherapy Plus Anti-PD-1 in Esophageal Squamous Cell Carcinoma

CYTOscore: A Triple-Cytokine Signature Predicts Survival and Response to Chemoradiotherapy Plus Anti-PD-1 in Esophageal Squamous Cell Carcinoma

A new serum cytokine-based risk score (CYTOscore) utilizing IL-8, CCL3, and CCL4 identifies ESCC patients likely to benefit from chemoradiotherapy combined with toripalimab, offering a non-invasive tool for personalized immunotherapy and pr

Section: GastroenterologyJan 20, 2026

Plasma Proteomics Unveils VEGFR1 as a High-Precision Prognostic Biomarker in Cardiogenic Shock

Plasma Proteomics Unveils VEGFR1 as a High-Precision Prognostic Biomarker in Cardiogenic Shock

A large-scale proteomic analysis identifies VEGFR1 as a significant, independent predictor of 180-day mortality in patients with cardiogenic shock, offering incremental prognostic value beyond traditional markers like serum lactate and SAPS

Section: CardiologyJan 19, 2026

Precision Medicine in Atrial Fibrillation: Biomarker-Based ABC-AF Risk Scores Fail to Outperform Standard Care

Precision Medicine in Atrial Fibrillation: Biomarker-Based ABC-AF Risk Scores Fail to Outperform Standard Care

A large-scale registry-based RCT reveals that tailoring atrial fibrillation treatment using the biomarker-driven ABC-AF risk score does not significantly reduce stroke or death compared to current standard guideline-based care, highlighting

Section: CardiologyJan 18, 2026

Prediabetes and Silent Cardiac Injury: A High-Risk Synergy for Heart Failure in Hypertensive Patients

Prediabetes and Silent Cardiac Injury: A High-Risk Synergy for Heart Failure in Hypertensive Patients

A post hoc analysis of the SPRINT trial reveals that the coexistence of prediabetes and subclinical myocardial injury or stress significantly escalates heart failure risk in hypertensive adults, suggesting a need for integrated glycemic and

Section: CardiologyJan 18, 2026

Serplulimab Plus Chemotherapy Sustains Survival Advantage in ES-SCLC: Insights from the ASTRUM-005 Trial and Novel Biomarker Profiles

Serplulimab Plus Chemotherapy Sustains Survival Advantage in ES-SCLC: Insights from the ASTRUM-005 Trial and Novel Biomarker Profiles

Updated ASTRUM-005 results confirm serplulimab’s significant survival benefit in extensive-stage small-cell lung cancer (15.8 vs. 11.1 months). Exploratory analyses identify a 15-protein signature and RB1/Notch mutations as potential predic

Section: newsJan 14, 2026

Serum Proteomic Changes Correlate with Baricitinib Efficacy in Juvenile Idiopathic Arthritis: Evidence from the JUVE-BASIS Trial

Serum Proteomic Changes Correlate with Baricitinib Efficacy in Juvenile Idiopathic Arthritis: Evidence from the JUVE-BASIS Trial

A post-hoc analysis of the Phase 3 JUVE-BASIS trial identifies key serum biomarkers, including CCL7, CCL18, and IL-6, that correlate with clinical response to baricitinib in JIA, suggesting potential pathways for personalized JAK inhibitor

Section: newsJan 13, 2026

Biomarkers of Benefit: tTMB and MSI Status Redefine Immunotherapy Success in Metastatic Castration-Resistant Prostate Cancer

Biomarkers of Benefit: tTMB and MSI Status Redefine Immunotherapy Success in Metastatic Castration-Resistant Prostate Cancer

A large-scale clinico-genomic study confirms that both tissue-based TMB and MSI-H independently predict significantly improved outcomes for ICI therapy in metastatic castration-resistant prostate cancer, while also validating blood-based MS

Section: newsJan 13, 2026

MSI-H and TMB-H as Independent Predictors: Refining Immunotherapy Selection in Metastatic Castration-Resistant Prostate Cancer

MSI-H and TMB-H as Independent Predictors: Refining Immunotherapy Selection in Metastatic Castration-Resistant Prostate Cancer

A large-scale clinico-genomic study demonstrates that both tissue-based MSI-H and TMB-H status independently predict superior outcomes for immune checkpoint inhibitors in mCRPC, while validating blood-based MSI as a viable alternative for p

Section: newsJan 13, 2026

Prev 1 2 3 4 Next